INTRODUCTION
Combination therapy using medications with complementary mechanisms of action is considered standard of care for the treatment of acne vulgaris, as it
addresses multiple pathogenic factors at the same time.1Topical retinoids, antibiotics, and benzoyl peroxide (BPO) are frequently used in varying combinations. Collectively, these drugs
address 3 of the 4 major pathogenic factors in acne; however,
none reduce sebum production. Topical retinoids normalize follicular hyperkeratinization2,3 while reducing inflammation by
downregulating Toll-like receptor activity.4 Topical antibiotics
lower colonization of Propionibacterium acnes on the skin and
its proinflammatory effects.1 Finally, BPO possesses keratolytic,
anti-inflammatory, and antimicrobial properties.5
There are several fixed-dose combination products commercially available to treat acne. One such product is the
combination of a topical retinoid with an antimicrobial agent.
Administered as a fixed-dose combination medication, these
ingredients have been shown to provide synergistic efficacy
as well as improved adherence compared with using the individual agents applied separately.6 In addition to their own
therapeutic properties, topical retinoids help maximize the
efficacy of concurrently applied antimicrobials by enhancing their skin penetration.7 While efficacious, unopposed
antibiotic use on the skin has been associated with the development microbial resistance,8 the addition of BPO to acne
regimens has been shown to reduce P acnes colonization on the skin and prevent antibiotic resistance.9-11 BPO has been
shown to be efficacious even in patients with previously
demonstrated P acnes resistance.12
Various BPO formulations exist, including leave-on and wash-off products. The major risk associated with the use of leave-on
BPO products is the development of application-site reactions,
which has been linked to the concentration of the BPO itself.13
True allergies to BPO are quite rare, and most skin reactions are
irritant in nature.14 The irritation potential of BPO can limit its
use in regimens containing retinoids, which can also lead to skin
irritation. Lack of adherence to the treatment regimen due to cutaneous adverse events is a major cause of treatment failure in acne
patients.15,16 For this reason, wash-off BPO products may be an appropriate choice for many patients. Some BPO cleansers, similar
to leave-on BPO-containing products, have demonstrated the ability to reduce P acnes colonization on the skin and to control the
development of acne lesions, even in patients with P acnes strains
shown to be resistant to tetracycline and macrolide antibiotics.17
In this report, we review the results of a single-blinded investigation to evaluate the safety and efficacy of combination therapy
using a fixed-dose combination tretinoin 0.025%/clindamcyin
phosphate 1.2% (T/CP) gel (ZIANA® Gel; Medicis Pharmaceutical Corporation, Scottsdale, AZ) in the evening compared with
the same fixed-dose combination T/CP gel in combination with a
BPO 6% cleansing cloth (TRIAZ® 6% Cleansing Cloths; Medicis).